These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 2099359)

  • 1. The effects of timolol on intraocular pressure and exercise heart rate in poor and extensive debrisoquine metabolizers.
    al-Sereiti MR; Edeki T; Lledo P; Turner P
    Int J Clin Pharmacol Res; 1990; 10(6):339-45. PubMed ID: 2099359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.
    Lewis RV; Lennard MS; Jackson PR; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1985 Mar; 19(3):329-33. PubMed ID: 2859048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction.
    Edeki TI; He H; Wood AJ
    JAMA; 1995 Nov 22-29; 274(20):1611-3. PubMed ID: 7474246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin.
    McGourty JC; Silas JH; Fleming JJ; McBurney A; Ward JW
    Clin Pharmacol Ther; 1985 Oct; 38(4):409-13. PubMed ID: 2864157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic absorption of ocular timolol in poor and extensive metabolizers of debrisoquine.
    Huupponen R; Kaila T; Lahdes K; Salminen L; Iisalo E
    J Ocul Pharmacol; 1991; 7(2):183-7. PubMed ID: 1919275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The influence of 0.85% RS-timolol and 0.5% S-timolol on intraocular pressure and systemic arterial blood pressure, heart rate, ECG, expiratory capacity in patients with ocular hypertension and primary open-angle glaucoma].
    Czechowicz-Janicka K; Staszkiewicz J; Strzałkowska M; Krajewska M; Popiołek B; Christman A
    Klin Oczna; 1999; 101(5):333-7. PubMed ID: 10714069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel.
    Uusitalo H; Niño J; Tahvanainen K; Turjanmaa V; Ropo A; Tuominen J; Kähönen M
    Acta Ophthalmol Scand; 2005 Dec; 83(6):723-8. PubMed ID: 16396651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of topical administration of a fixed combination of dorzolamide-timolol to monotherapy with timolol or dorzolamide on IOP, pupil size, and heart rate in glaucomatous dogs.
    Plummer CE; MacKay EO; Gelatt KN
    Vet Ophthalmol; 2006; 9(4):245-9. PubMed ID: 16771760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of D-timolol on intraocular pressure, heart rate, cardiac contractility, and tracheal muscle function.
    Chiou GC
    Curr Eye Res; 1982-1983; 2(8):507-10. PubMed ID: 7184703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of the beta-2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects.
    Fuchsjager-Mayrl G; Markovic O; Losert D; Lucas T; Wachek V; Muller M; Schmetterer L
    Mol Vis; 2005 Sep; 11():811-5. PubMed ID: 16205624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
    Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
    Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Modification in amplitude of nycthemeral changes in intraocular pressure under timolol].
    Martin X; Rabineau PA
    J Fr Ophtalmol; 1988; 11(12):843-8. PubMed ID: 3075625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timolol maleate: side effects on healthy nonglaucomatous volunteers.
    Davidson J; Ribak J; Eckstein D; Barishak R
    Aviat Space Environ Med; 1983 Apr; 54(4):360-2. PubMed ID: 6133515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops.
    Korte JM; Kaila T; Saari KM
    Graefes Arch Clin Exp Ophthalmol; 2002 Jun; 240(6):430-5. PubMed ID: 12107508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population study of poor debrisoquine-type metabolizers of propranolol among Japanese.
    Hayashi M; Takase M
    Jpn J Ophthalmol; 1985; 29(3):272-81. PubMed ID: 4079124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days.
    McCrea JB; Vlasses PH; Franz TJ; Zeoli L
    Pharmacotherapy; 1990; 10(4):289-93. PubMed ID: 2388875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of topical nipradilol and timolol maleate on intraocular pressure, facility of outflow, arterial blood pressure and pulse rate in dogs.
    Maehara S; Ono K; Ito N; Tsuzuki K; Seno T; Yokoyama T; Yamashita K; Izumisawa Y; Kotani T
    Vet Ophthalmol; 2004; 7(3):147-50. PubMed ID: 15091320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
    Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timolol metabolism and debrisoquine oxidation polymorphism: a population study.
    Lennard MS; Lewis RV; Brawn LA; Tucker GT; Ramsay LE; Jackson PR; Woods HF
    Br J Clin Pharmacol; 1989 Apr; 27(4):429-34. PubMed ID: 2719899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.